Common questions about Binocrit (FAQ)
Q: Do I need to take iron supplements while I am being treated with Binocrit?
A: Regulatory information consistently states that certain co-factors, such as iron, are necessary for the medicine to work as intended. If a deficiency exists, correction of the deficiency is required, and this is often achieved through iron supplementation.
Q: Does Binocrit interact with common blood pressure medications?
A: Official documents do not indicate that Epoetin alfa alters the metabolism of other drugs. However, a common side effect of the medicine is an increase or aggravation of existing blood pressure (Hypertension). Due to the potential for increased blood pressure, close monitoring and possible adjustment of existing blood pressure medication doses are regulatory requirements.
Q: Is there a known interaction between Binocrit and cyclosporin?
A: Co-administration with the immunosuppressant medicine Ciclosporin may alter the blood levels of Ciclosporin. Official documents state that frequent monitoring of Ciclosporin concentrations is required to manage this effect.
Q: Why do some people on dialysis receive Binocrit intravenously and others inject it subcutaneously?
A: Both Intravenous (IV) and Subcutaneous (SC) routes are approved methods of administration. Official instructions state that the IV route is generally preferred for patients who are on haemodialysis. Official instructions specify that the choice of route is determined by the patient's specific clinical situation.
Q: What are the serious but rare skin reactions that have been reported with epoetin treatments?
A: Serious but rare skin reactions have been reported in the post-marketing setting for the epoetin alfa class of medicines. These include blistering and skin exfoliation reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Q: How long does the active substance, epoetin alfa, stay in the body?
A: Pharmacokinetic studies—which examine how a substance moves through the body—indicate that intravenously administered epoetin alfa has a circulating half-life ranging from approximately 4 to 13 hours in patients with chronic renal failure.
Q: Does Binocrit contain any ingredients that could be an issue for people with a latex allergy?
A: The official product information should be consulted to check for the presence or absence of natural rubber latex in the needle shield or plunger of the syringe. It is important to check the official product information for the presence or absence of natural rubber latex in the syringe components.
Q: What are the official recommendations regarding the use of Binocrit in elderly patients?
A: Official product information does not specify dose adjustments solely based on advanced age. Dosage adjustment is primarily determined by the patient's hemoglobin level and their clinical response to the medicine, not age alone.
Q: What are the storage requirements for Binocrit pre-filled syringes?
A: While Binocrit must be stored long-term in a refrigerator (2°C to 8°C), official information allows it to be removed and kept at room temperature (up to 25°C) for one single period of up to 3 days. After this time, it is required to be used or discarded.
Q: Can Binocrit be used to treat anemia caused by things other than kidney failure or chemotherapy?
A: In addition to chronic kidney failure and chemotherapy-induced anemia, the active substance epoetin alfa is also approved in some regions for other uses. These include treating anemia associated with Zidovudine in HIV-infected patients and reducing the need for red blood cell transfusions in certain adults undergoing elective surgery.
Q: How quickly should I expect to see an improvement in my energy levels after starting Binocrit?
A: Clinical information indicates that a significant increase in red blood cell production is usually observed within 2 to 6 weeks. The timeframe of 2 to 6 weeks aligns with when an improvement in anemia-related symptoms, such as fatigue and low energy, may become apparent.
Q: What are the cardiovascular risks associated with using Binocrit, according to official documents?
A: Regulatory documents list several serious adverse reactions related to the vascular system. These cardiovascular risks include an increased potential for Myocardial Infarction (heart attack), Stroke, and Venous Thromboembolism (blood clots).
Q: Is Binocrit safe for patients who have a history of blood clots?
A: Official documents indicate that the medicine should be administered with caution in patients with a history of thrombotic (blood clot) events due to a potential for increased risk of thrombotic events.
Q: Is it possible to become allergic to the active ingredient (epoetin alfa)?
A: The formation of anti-erythropoietin antibodies is listed in regulatory texts as a rare reaction to epoetin alfa medicines. This immune response is associated with the potential for a very severe form of anemia known as Pure Red Cell Aplasia (PRCA).
Q: Is Binocrit safe for children with chronic kidney failure?
A: Official eligibility rules indicate the medicine is approved for use in children aged 1 to 18 years who have chronic kidney disease and are on haemodialysis. Use is not established in infants under one year old.
Q: How does Binocrit help patients who are preparing for major surgery?
A: For patients undergoing major elective surgery, the medicine is used to help the body prepare for potential blood loss. The goal is to reduce the need for allogeneic red blood cell transfusions (blood from a donor) in those with moderate anemia and a high risk of blood loss.
Q: What is the significance of the haemoglobin level when starting and continuing treatment?
A: The hemoglobin level is a crucial measurement used to guide treatment throughout the course of therapy. Official documents specify a desired concentration range (e.g., 10 to 12 g/dL) that is targeted to manage anemia symptoms while respecting the threshold for avoiding the risk of serious adverse events.
Q: What are the key findings from the studies that established Binocrit's efficacy?
A: Binocrit is a biosimilar medicine, and its core clinical studies focused on comparability. The key findings established that its safety and effectiveness profile was comparable to the reference epoetin alfa product, demonstrating equivalence in achieving and maintaining target Hemoglobin levels.
Q: Why is it true that Binocrit works by stimulating bone marrow?
A: Binocrit's active ingredient targets receptors in the bone marrow to initiate the body's natural sequence for red blood cell production, a process called erythropoiesis. This stimulation promotes the survival and proliferation of immature red blood cells, ultimately correcting the red blood cell deficit.
Q: Why do some patients need to use Binocrit only temporarily (like before surgery) while others use it long-term?
A: The duration of use depends on the underlying medical condition. For chronic conditions like kidney failure, treatment is often long-term. In contrast, for purposes like preventing blood loss before major surgery, the use is restricted to a specific short-term period around the procedure.
Q: Does the body produce antibodies against epoetin alfa after long-term use?
A: The formation of anti-erythropoietin antibodies is listed in regulatory texts as a rare adverse reaction. These antibodies are sometimes associated with the development of Pure Red Cell Aplasia (PRCA), a severe condition where the body stops producing red blood cells.
Q: Why does the Binocrit package leaflet mention a potential risk for patients with gout or porphyria?
A: Regulatory documents advise caution for patients with Porphyria, as treatment has been rarely associated with an exacerbation of this specific inherited blood disorder.
Q: Are there different injection sites recommended for subcutaneous administration?
A: For subcutaneous injection, recommended sites include the abdomen, the front of the middle thighs, the outer area of the upper arms, and the upper outer area of the buttocks. Injection sites should be rotated.
Q: What is the recommended maximum volume for a single subcutaneous injection?
A: General administration guidelines suggest that the volume for each subcutaneous injection should typically not exceed 1 mL. This is a standard limit to help ensure proper absorption and patient comfort.
Q: Does Binocrit affect the ability to drive or operate machinery?
A: Official product information, specifically for the active substance Epoetin alfa, states that it is expected to have no or negligible influence on a person's ability to drive or operate machinery.
Q: Can Binocrit treatment be stopped suddenly or must it be tapered?
A: Official instructions specify that if the hemoglobin level rises to exceed a specific regulatory threshold (e.g., 13 g/dL), the medicine is to be discontinued immediately. Reinitiation of therapy at a reduced dose is then conducted once the level falls back within the target range.
